# US 2018/0022728 A1 · Glutarimide Derivatives, Use Thereof, Pharmaceutical Composition Based Thereon and Methods for Producing Glutarimide Derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0022728 A1
- Document ID: US20180022728A1
- Status: Published application
- Kind: A1
- Application number: 15/718,274
- Filed: 2017-09-28
- Published: 2018-01-25
- Earliest claimed: 2013-04-12
- Assignees: Obschestvo S Ogranichennoi Otvetstvennostiyu “Pharmenterprises”
- Applicants: Obschestvo S Ogranichennoi Otvetstvennostiyu "Pharmenterprises"
- Inventors: Vladimir Evgenievich Nebolsin; Tatyana Alexandrovna Kromova
- Web page: https://patentgrep.com/patent/US20180022728A1

## CPC

- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 11/04: for throat disorders
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 31/16: for influenza or rhinoviruses
- C07D 401/14: containing three or more hetero rings
- C07D 405/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 409/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 413/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 417/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 453/02: containing not further condensed quinuclidine ring systems
- C07D 471/04: Ortho-condensed systems
- C07D 487/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A compound having the following formula: or a pharmaceutically acceptable salt thereof. A medicament or pharmaceutical composition contains the compound. A method of treating a respiratory tract disease includes administering to a patient an effective amount of a compound or a pharmaceutically acceptable salt thereof

## Claims

### Claim 1

A compound having the following formula:
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

A medicament for the treatment of a respiratory tract disease, which is a compound or a pharmaceutically acceptable salt thereof of claim 1.

### Claim 3 (depends on 2)

The medicament of claim 2, wherein the respiratory tract disease is rhinosinusitis.

### Claim 4 (depends on 2)

The medicament of claim 2, wherein the respiratory tract disease is caused by an RNA-comprising virus.

### Claim 5 (depends on 4)

The medicament of claim 4, wherein the virus is selected from the group consisting of rhinovirus, Coxsackie virus, and influenza virus.

### Claim 6 (depends on 2)

The medicament of claim 2, wherein the disease is exacerbations of asthma, chronic obstructive pulmonary disease, bronchitis and mucoviscidosis, which are caused by rhinovirus, influenza virus and/or respiratory syncytial virus.

### Claim 7 (depends on 1)

A pharmaceutical composition for the treatment of a respiratory tract disease, comprising an effective amount of a compound or a pharmaceutically acceptable salt thereof of claim 1, and a pharmaceutically acceptable carrier.

### Claim 8 (depends on 7)

The pharmaceutical composition of claim 7, wherein the respiratory tract disease is rhinosinusitis.

### Claim 9 (depends on 7)

The pharmaceutical composition of claim 7, wherein the respiratory tract disease is caused by an RNA-comprising virus.

### Claim 10 (depends on 9)

The pharmaceutical composition of claim 9, wherein the virus is selected from the group consisting of rhinovirus, Coxsackie virus, and influenza.

### Claim 11 (depends on 7)

The pharmaceutical composition of claim 7, wherein the disease is exacerbations of asthma, chronic obstructive pulmonary disease, bronchitis and mucoviscidosis, which are caused by rhinovirus, influenza virus and/or respiratory syncytial virus.

### Claim 12 (depends on 1)

A method of treating a respiratory tract disease, comprising administering to a patient an effective amount of a compound or a pharmaceutically acceptable salt thereof of claim 1.

### Claim 13 (depends on 12)

The method of claim 12, wherein the respiratory tract disease is rhinosinusitis.

### Claim 14 (depends on 12)

The method of claim 12, wherein the respiratory tract disease is caused by an RNA-comprising virus.

### Claim 15 (depends on 14)

The method of claim 14, wherein the virus is selected from the group consisting of rhinovirus, Coxsackie virus, and influenza virus.

### Claim 16 (depends on 12)

The method of claim 12, wherein the disease is exacerbations of asthma, chronic obstructive pulmonary disease, bronchitis and mucoviscidosis, which are caused by rhinovirus, influenza virus and/or respiratory syncytial virus.